Stock Movers Boeing Jumps, Janux Therapeutics Plunges, Signet Slides
Dec 2, 2025
Boeing shares surged 9.2% after revealing positive cash flow projections for 2026, easing investor worries. Meanwhile, Janux Therapeutics experienced a staggering 41% drop in shares following disappointing trial results for its prostate cancer treatment. Signet Jewelry's forecast for holiday sales raised concerns, with a 4.1% dip in shares attributed to external market conditions and waning consumer confidence. The hosts also discussed the impact of lab-grown diamonds on traditional jewelry retailers.
AI Snips
Chapters
Transcript
Episode notes
Boeing’s Cash Flow Reassurance
- Boeing signaled a return to positive free cash flow in 2026, calming investor concerns after recent cash burn.
- The CFO projected low-single-digit billions in free cash flow, lifting the stock to its best day since April.
Biotech Shock From Disappointing Trial Data
- Janux Therapeutics dumped after interim trial data disappointed investors in an early-stage prostate cancer study.
- The stock plunged up to about half its value and is down roughly 69% year to date.
Single-Drug Risk For Small Biotechs
- Small biotechs often hinge on single drug readouts, making their stocks highly volatile.
- Janux's heavy year-to-date decline illustrates how quickly investor sentiment can turn on clinical results.